nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—MTOR—AMPK Signaling—TP53—meningioma	0.0024	0.0024	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—PTEN—meningioma	0.0024	0.0024	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—PTEN—meningioma	0.00239	0.00239	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—PTEN—meningioma	0.00238	0.00238	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.00234	0.00234	CbGpPWpGaD
Sirolimus—FGF2—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	0.00234	0.00234	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CST3—meningioma	0.00233	0.00233	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—ERBB2—meningioma	0.00233	0.00233	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—CTSL—meningioma	0.00233	0.00233	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	0.00232	0.00232	CbGpPWpGaD
Sirolimus—FGF2—Constitutive PI3K/AKT Signaling in Cancer—AKT1—meningioma	0.00229	0.00229	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.00223	0.00223	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—PTEN—meningioma	0.00223	0.00223	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—PTEN—meningioma	0.00223	0.00223	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—ERBB2—meningioma	0.00223	0.00223	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—PTEN—meningioma	0.00221	0.00221	CbGpPWpGaD
Sirolimus—MTOR—IL4-mediated signaling events—AKT1—meningioma	0.00221	0.00221	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—ERBB2—meningioma	0.0022	0.0022	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—PTEN—meningioma	0.0022	0.0022	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AP1B1—meningioma	0.00219	0.00219	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—PTEN—meningioma	0.00219	0.00219	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TSHB—meningioma	0.00216	0.00216	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—CST3—meningioma	0.00214	0.00214	CbGpPWpGaD
Sirolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—meningioma	0.00213	0.00213	CbGpPWpGaD
Sirolimus—MTOR—mTOR signaling pathway—AKT1—meningioma	0.0021	0.0021	CbGpPWpGaD
Sirolimus—MTOR—TSH signaling pathway—AKT1—meningioma	0.0021	0.0021	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.0021	0.0021	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—ERBB2—meningioma	0.0021	0.0021	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—meningioma	0.0021	0.0021	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—ERBB2—meningioma	0.00209	0.00209	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—ERBB2—meningioma	0.00209	0.00209	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—ERBB2—meningioma	0.00208	0.00208	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—PTEN—meningioma	0.00207	0.00207	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—ERBB2—meningioma	0.00207	0.00207	CbGpPWpGaD
Sirolimus—FGF2—PI-3K cascade—AKT1—meningioma	0.00207	0.00207	CbGpPWpGaD
Sirolimus—MTOR—Regulation of Telomerase—AKT1—meningioma	0.00205	0.00205	CbGpPWpGaD
Sirolimus—MTOR—Costimulation by the CD28 family—AKT1—meningioma	0.00205	0.00205	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—ERBB2—meningioma	0.00204	0.00204	CbGpPWpGaD
Sirolimus—MTOR—SREBP signalling—AKT1—meningioma	0.00203	0.00203	CbGpPWpGaD
Sirolimus—MTOR—AMPK Signaling—AKT1—meningioma	0.00203	0.00203	CbGpPWpGaD
Sirolimus—MTOR—Disease—AP1B1—meningioma	0.00203	0.00203	CbGpPWpGaD
Sirolimus—FGF2—PI3K/AKT activation—AKT1—meningioma	0.00202	0.00202	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—HES1—meningioma	0.00201	0.00201	CbGpPWpGaD
Sirolimus—FGF2—GAB1 signalosome—AKT1—meningioma	0.002	0.002	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CD34—meningioma	0.002	0.002	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—PTEN—meningioma	0.00199	0.00199	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	0.00198	0.00198	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—PDGFB—meningioma	0.00198	0.00198	CbGpPWpGaD
Sirolimus—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—meningioma	0.00196	0.00196	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of mRNA—AKT1—meningioma	0.00195	0.00195	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—ERBB2—meningioma	0.00194	0.00194	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—ERBB2—meningioma	0.00194	0.00194	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—ERBB2—meningioma	0.00194	0.00194	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—ERBB2—meningioma	0.00193	0.00193	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—ERBB2—meningioma	0.00191	0.00191	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTSL—meningioma	0.0019	0.0019	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—PTEN—meningioma	0.0019	0.0019	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—ERBB2—meningioma	0.0019	0.0019	CbGpPWpGaD
Sirolimus—MTOR—Leptin signaling pathway—AKT1—meningioma	0.0019	0.0019	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.00189	0.00189	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—PTEN—meningioma	0.00188	0.00188	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—PTEN—meningioma	0.00187	0.00187	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—SMO—meningioma	0.00184	0.00184	CbGpPWpGaD
Sirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—meningioma	0.0018	0.0018	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—ERBB2—meningioma	0.0018	0.0018	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—PTEN—meningioma	0.0018	0.0018	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—PTEN—meningioma	0.00179	0.00179	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—ERBB2—meningioma	0.00179	0.00179	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—PTEN—meningioma	0.00178	0.00178	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—PTEN—meningioma	0.00178	0.00178	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—PTEN—meningioma	0.00177	0.00177	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—PTEN—meningioma	0.00176	0.00176	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PGR—meningioma	0.00176	0.00176	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PTEN—meningioma	0.00174	0.00174	CbGpPWpGaD
Sirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	0.00173	0.00173	CbGpPWpGaD
Sirolimus—MTOR—CXCR4-mediated signaling events—AKT1—meningioma	0.00173	0.00173	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	0.00172	0.00172	CbGpPWpGaD
Sirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—meningioma	0.00172	0.00172	CbGpPWpGaD
Sirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—meningioma	0.0017	0.0017	CbGpPWpGaD
Sirolimus—EIF4E—Metabolism of RNA—AKT1—meningioma	0.00167	0.00167	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—PTEN—meningioma	0.00166	0.00166	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—PTEN—meningioma	0.00166	0.00166	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PTEN—meningioma	0.00166	0.00166	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—PTEN—meningioma	0.00164	0.00164	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—PTEN—meningioma	0.00163	0.00163	CbGpPWpGaD
Sirolimus—FGF2—Disease—CST3—meningioma	0.00162	0.00162	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—PTEN—meningioma	0.00162	0.00162	CbGpPWpGaD
Sirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.0016	0.0016	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PDGFB—meningioma	0.00159	0.00159	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TSHB—meningioma	0.00158	0.00158	CbGpPWpGaD
Sirolimus—FGF2—Signaling by SCF-KIT—AKT1—meningioma	0.00154	0.00154	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—PTEN—meningioma	0.00153	0.00153	CbGpPWpGaD
Sirolimus—MTOR—PI-3K cascade—AKT1—meningioma	0.00153	0.00153	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—PTEN—meningioma	0.00152	0.00152	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PDGFB—meningioma	0.00152	0.00152	CbGpPWpGaD
Sirolimus—MTOR—PI3K/AKT activation—AKT1—meningioma	0.0015	0.0015	CbGpPWpGaD
Sirolimus—MTOR—GAB1 signalosome—AKT1—meningioma	0.00149	0.00149	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CD34—meningioma	0.00148	0.00148	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling of activated FGFR—AKT1—meningioma	0.00148	0.00148	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	0.00147	0.00147	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PDGFB—meningioma	0.00146	0.00146	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB4—AKT1—meningioma	0.00145	0.00145	CbGpPWpGaD
Sirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—meningioma	0.00145	0.00145	CbGpPWpGaD
Sirolimus—MTOR—ErbB1 downstream signaling—AKT1—meningioma	0.00145	0.00145	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.00143	0.00143	CbGpPWpGaD
Sirolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—meningioma	0.00143	0.00143	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALAD—meningioma	0.00142	0.00142	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTSL—meningioma	0.00141	0.00141	CbGpPWpGaD
Sirolimus—FGF2—Downstream signal transduction—AKT1—meningioma	0.00139	0.00139	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR—AKT1—meningioma	0.00138	0.00138	CbGpPWpGaD
Sirolimus—FGF2—Signaling by ERBB2—AKT1—meningioma	0.00138	0.00138	CbGpPWpGaD
Sirolimus—FGF2—DAP12 signaling—AKT1—meningioma	0.00137	0.00137	CbGpPWpGaD
Sirolimus—MTOR—Signaling by VEGF—AKT1—meningioma	0.00135	0.00135	CbGpPWpGaD
Sirolimus—FGF2—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.00135	0.00135	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SMO—meningioma	0.00135	0.00135	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—ERBB2—meningioma	0.00132	0.00132	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALAD—meningioma	0.0013	0.0013	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PGR—meningioma	0.00129	0.00129	CbGpPWpGaD
Sirolimus—FGF2—DAP12 interactions—AKT1—meningioma	0.00129	0.00129	CbGpPWpGaD
Sirolimus—FGF2—Signaling by FGFR in disease—AKT1—meningioma	0.00129	0.00129	CbGpPWpGaD
Sirolimus—FGF2—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.00129	0.00129	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—meningioma	0.00129	0.00129	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR—AKT1—meningioma	0.00128	0.00128	CbGpPWpGaD
Sirolimus—FGF2—Signaling by EGFR in Cancer—AKT1—meningioma	0.00127	0.00127	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HES1—meningioma	0.00126	0.00126	CbGpPWpGaD
Sirolimus—FGF2—Signaling by PDGF—AKT1—meningioma	0.00126	0.00126	CbGpPWpGaD
Sirolimus—FGF2—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.00121	0.00121	CbGpPWpGaD
Sirolimus—MTOR—Disease—CST3—meningioma	0.0012	0.0012	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HES1—meningioma	0.0012	0.0012	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TSHB—meningioma	0.0012	0.0012	CbGpPWpGaD
Sirolimus—FGF2—B Cell Activation—AKT1—meningioma	0.00119	0.00119	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—ERBB2—meningioma	0.00115	0.00115	CbGpPWpGaD
Sirolimus—MTOR—Signaling by SCF-KIT—AKT1—meningioma	0.00115	0.00115	CbGpPWpGaD
Sirolimus—FGF2—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.00114	0.00114	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—PTEN—meningioma	0.00113	0.00113	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PDGFB—meningioma	0.00113	0.00113	CbGpPWpGaD
Sirolimus—MTOR—BDNF signaling pathway—AKT1—meningioma	0.00113	0.00113	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling of activated FGFR—AKT1—meningioma	0.0011	0.0011	CbGpPWpGaD
Sirolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—meningioma	0.00109	0.00109	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PDGFB—meningioma	0.00108	0.00108	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB4—AKT1—meningioma	0.00108	0.00108	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PDGFB—meningioma	0.00108	0.00108	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—ERBB2—meningioma	0.00107	0.00107	CbGpPWpGaD
Sirolimus—MTOR—Insulin Signaling—AKT1—meningioma	0.00104	0.00104	CbGpPWpGaD
Sirolimus—MTOR—Downstream signal transduction—AKT1—meningioma	0.00103	0.00103	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PDGFB—meningioma	0.00103	0.00103	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR—AKT1—meningioma	0.00103	0.00103	CbGpPWpGaD
Sirolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—meningioma	0.00103	0.00103	CbGpPWpGaD
Sirolimus—MTOR—Signaling by ERBB2—AKT1—meningioma	0.00102	0.00102	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SMO—meningioma	0.00102	0.00102	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—ERBB2—meningioma	0.00102	0.00102	CbGpPWpGaD
Sirolimus—MTOR—DAP12 signaling—AKT1—meningioma	0.00102	0.00102	CbGpPWpGaD
Sirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—meningioma	0.001	0.001	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PGR—meningioma	0.000978	0.000978	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—ERBB2—meningioma	0.000978	0.000978	CbGpPWpGaD
Sirolimus—MTOR—DAP12 interactions—AKT1—meningioma	0.000956	0.000956	CbGpPWpGaD
Sirolimus—MTOR—Signaling by FGFR in disease—AKT1—meningioma	0.000956	0.000956	CbGpPWpGaD
Sirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.000956	0.000956	CbGpPWpGaD
Sirolimus—FGF2—Disease—HES1—meningioma	0.000955	0.000955	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR—AKT1—meningioma	0.000947	0.000947	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALAD—meningioma	0.000943	0.000943	CbGpPWpGaD
Sirolimus—MTOR—Signaling by EGFR in Cancer—AKT1—meningioma	0.000939	0.000939	CbGpPWpGaD
Sirolimus—MTOR—Signaling by PDGF—AKT1—meningioma	0.000935	0.000935	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TSHB—meningioma	0.000916	0.000916	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—PTEN—meningioma	0.00091	0.00091	CbGpPWpGaD
Sirolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—meningioma	0.000906	0.000906	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TSHB—meningioma	0.000891	0.000891	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PDGFB—meningioma	0.000885	0.000885	CbGpPWpGaD
Sirolimus—MTOR—B Cell Activation—AKT1—meningioma	0.000884	0.000884	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HES1—meningioma	0.000883	0.000883	CbGpPWpGaD
Sirolimus—FGF2—Signaling by NGF—AKT1—meningioma	0.000877	0.000877	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—PTEN—meningioma	0.000868	0.000868	CbGpPWpGaD
Sirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.000846	0.000846	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TSHB—meningioma	0.000841	0.000841	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—PTEN—meningioma	0.000834	0.000834	CbGpPWpGaD
Sirolimus—MTOR—Cellular responses to stress—TP53—meningioma	0.000822	0.000822	CbGpPWpGaD
Sirolimus—FGF2—Disease—PDGFB—meningioma	0.000817	0.000817	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.000788	0.000788	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SMO—meningioma	0.000757	0.000757	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—ERBB2—meningioma	0.000756	0.000756	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PDGFB—meningioma	0.000755	0.000755	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PGR—meningioma	0.000726	0.000726	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—ERBB2—meningioma	0.000726	0.000726	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—ERBB2—meningioma	0.000722	0.000722	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALAD—meningioma	0.000712	0.000712	CbGpPWpGaD
Sirolimus—MTOR—Disease—HES1—meningioma	0.000709	0.000709	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—ERBB2—meningioma	0.00069	0.00069	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.000672	0.000672	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HES1—meningioma	0.000669	0.000669	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PDGFB—meningioma	0.000657	0.000657	CbGpPWpGaD
Sirolimus—MTOR—Signaling by NGF—AKT1—meningioma	0.000651	0.000651	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PTEN—meningioma	0.000644	0.000644	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PTEN—meningioma	0.000619	0.000619	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PTEN—meningioma	0.000616	0.000616	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TSHB—meningioma	0.000608	0.000608	CbGpPWpGaD
Sirolimus—MTOR—Disease—PDGFB—meningioma	0.000606	0.000606	CbGpPWpGaD
Sirolimus—FGF2—Immune System—ERBB2—meningioma	0.000593	0.000593	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PTEN—meningioma	0.000588	0.000588	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PDGFB—meningioma	0.000572	0.000572	CbGpPWpGaD
Sirolimus—FGF2—Developmental Biology—AKT1—meningioma	0.000567	0.000567	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—meningioma	0.00056	0.00056	CbGpPWpGaD
Sirolimus—FGF2—Disease—ERBB2—meningioma	0.000548	0.000548	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—meningioma	0.000524	0.000524	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—meningioma	0.000521	0.000521	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—meningioma	0.000506	0.000506	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PTEN—meningioma	0.000506	0.000506	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—meningioma	0.0005	0.0005	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HES1—meningioma	0.000496	0.000496	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—meningioma	0.00048	0.00048	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTEN—meningioma	0.000467	0.000467	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TSHB—meningioma	0.000459	0.000459	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	0.000458	0.000458	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—meningioma	0.00044	0.00044	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALAD—meningioma	0.000438	0.000438	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTEN—meningioma	0.000431	0.000431	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PDGFB—meningioma	0.000425	0.000425	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—meningioma	0.000406	0.000406	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—meningioma	0.000401	0.000401	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	0.000387	0.000387	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—meningioma	0.000383	0.000383	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—meningioma	0.000375	0.000375	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—meningioma	0.000371	0.000371	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—meningioma	0.000357	0.000357	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—meningioma	0.000355	0.000355	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—meningioma	0.000346	0.000346	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—meningioma	0.000339	0.000339	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—meningioma	0.000327	0.000327	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—meningioma	0.000294	0.000294	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—meningioma	0.000291	0.000291	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—meningioma	0.000285	0.000285	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TSHB—meningioma	0.000283	0.000283	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—meningioma	0.000269	0.000269	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—meningioma	0.00025	0.00025	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—meningioma	0.000249	0.000249	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—meningioma	0.000243	0.000243	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—meningioma	0.000229	0.000229	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—meningioma	0.000223	0.000223	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—meningioma	0.000216	0.000216	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—meningioma	0.0002	0.0002	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—meningioma	0.000188	0.000188	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—meningioma	0.000166	0.000166	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—meningioma	0.000166	0.000166	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—meningioma	0.000144	0.000144	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—meningioma	0.00014	0.00014	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—meningioma	0.000132	0.000132	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—meningioma	0.000125	0.000125	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—meningioma	9.54e-05	9.54e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—meningioma	7.7e-05	7.7e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—meningioma	7.2e-05	7.2e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—meningioma	4.44e-05	4.44e-05	CbGpPWpGaD
